What is the level of liabilities of Insmed this year?
Insmed has a debt balance of 1.66 B USD this year.
Insmed Liabilities 2024
Insmed Liabilities
1.66 B USD
Ticker
INSM
ISIN
US4576693075
WKN
A1JJA3
In 2024, Insmed's total liabilities amounted to 1.66 B USD, a 5.95% difference from the 1.57 B USD total liabilities in the previous year.
Insmed Aktienanalyse
What does Insmed do?
Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Insmed's Liabilities
Insmed's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Insmed's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Insmed's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Insmed's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Insmed’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Insmed stock
What were the liabilities of Insmed compared to the previous year?
The liabilities of Insmed have increased by 5.95% increased compared to the previous year.
What are the consequences of high debt for investors of Insmed?
High liabilities can pose a risk for investors of Insmed, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Insmed?
Low liabilities mean that Insmed has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Insmed affect the company?
An increase in liabilities of Insmed can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Insmed affect the company?
A decrease in the liabilities of Insmed can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Insmed?
Some factors that can influence the liabilities of Insmed include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Insmed so important for investors?
The liabilities of Insmed are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Insmed take to modify the liabilities?
To change its liabilities, Insmed can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Insmed pay?
Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.
What is the dividend yield of Insmed?
The current dividend yield of Insmed is .
When does Insmed pay dividends?
Insmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insmed?
Insmed paid dividends every year for the past 0 years.
What is the dividend of Insmed?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insmed located?
Insmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insmed from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.
When did Insmed pay the last dividend?
The last dividend was paid out on 10/28/2024.
What was the dividend of Insmed in the year 2023?
In the year 2023, Insmed distributed 0 USD as dividends.
In which currency does Insmed pay out the dividend?
The dividends of Insmed are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Insmed
Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
